Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Rental Rate Antitrust Lawsuit
    • Automobile 3G Network Shutdown Lawsuit
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all blog posts
11.13.2013

Proposed FDA Rule Allows Generic Drug Manufacturers to Update Labeling

By Corey Lorenz, Associate
You Should Know, For Consumers

After much anticipation, the U.S. Food and Drug Administration (FDA) has taken action to place responsibility on generic drug manufacturers to provide adequate warnings to consumers, and hold them legally liable for their failure to do so.  Currently, federal law requires generic drug labeling to match that of their brand-name counterpart, and as a result the Supreme Court held in PLIVA v. Mensing that failure-to-warn claims cannot be brought against the generic drug-maker.  The seeming injustice resulting from this has been a source of controversy and advocacy over the years.  Taking a significant step forward to protect consumers, the FDA has made public a proposed rule on generic drug labeling that could effectively overturn Mensing and provide legal remedy those that have been injured after consuming a generic drug.

The FDA’s proposed rule would allow generic drug manufacturers to initiate changes to their own labeling by submitting a CBE (changes being effected) supplement.  Currently, they cannot initiate those changes on their own and must wait for their brand-name counterpart to do so.  In drafting this rule the FDA illustrates their awareness that not only does the current law leave many consumers without legal recourse, but it fails to create any incentive for generic manufacturers to work in coordination with the FDA to market and label their products safely.  Taking into account that there is little incentive to comply with post-market requirements and ensure that their labels are accurate and up to date, this proposed rule was designed to “create parity” between generic and brand-name manufacturers.  Allowing generic manufacturers to unilaterally initiate changes to product labeling could eliminate the preemption of failure-to-warn clams related to generic drugs.

This proposed rule is not official yet.  First, there is a 60 day time-period where comments can be submitted on the proposed rule.  After this time, the FDA will review the comments and publish a final rule.  This issue is extremely important, and a final rule allowing these changes could potentially protect the legal rights of generic drug users which accounts for over 80% of all prescriptions filled in the United States.  It also ensures that generic drug-makers are responsible and accountable for their products.  The American Associate for Justice is a primary group promoting the implementation of this rule.  To continue their advocacy on this issue, they have created a petition that you can access and participate in by clicking here.

Photo Credit: Ben Harvey

Share

No Comments

Leave a Reply Cancel reply

Receive News Updates

Get the latest from Wexler Wallace LLP & stay informed.

Categories

  • Media Appearances
  • Uncategorized
  • Columns
    • Guest Post
    • Ken Wexler
  • Cases
  • Hall Of Shame
    • Villain Of The Week
  • In The News
    • Public Victories
  • The Firm
    • Around The World
    • Chicago
  • You Should Know
    • For Investors
    • For Businesses
    • For Consumers
  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2023 © Wexler Boley & Elgersma LLP

Wexler Boley & Elgersma uses cookies to improve the performance and functionality of this site. By using our website, you are providing us with your consent to use cookies on this site. Close Privacy Policy
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT